Clinical Trials

Docosahexaenoic acid (DHA) is a nutrient found in some fish and eggs and its intake in US diets is typically low. Because DHA is important for early brain development, it has recently been added to many prenatal supplements. The usual amount is around 200 mg/day. Participants in this study are guaranteed to receive at least 200 mg/day of DHA. Almost 5 in 100 births in the US occur before 34 weeks of pregnancy. There is no way to predict which births will occur before 34 weeks. In an earlier study conducted at the University of Kansas Medical Center, women who received 600 mg DHA/day compared to no DHA had fewer births before 34 weeks of pregnancy with fewer complications of preterm birth. This study is designed to compare standard care (200 mg/day of DHA) to a higher amount of DHA (1000 mg/day) to determine if the higher amount will reduce early preterm birth (birth before 34 weeks of pregnancy). Individual participation in this study is expected last about 5 months.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

This phase II Lung-MAP non-Match treatment trial studies how well ramucirumab and pembrolizumab work versus standard of care in treating patients with non-small cell lung cancer that is stage IV or has come back. Immunotherapy with monoclonal antibodies, such as ramucirumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in standard of care chemotherapy for non-small cell lung cancer, such as docetaxel, gemcitabine hydrochloride, and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ramucirumab and pembrolizumab together may work better in treating patients with non-small lung cancer compared to standard of care.

MC - Chippewa Falls Center

2655 CTY HWY I

CHIPPEWA FALLS, WI 54729

MC - Wausau Center

2727 PLAZA DRIVE

WAUSAU, WI 54401

MC - Wisconsin Rapids Center

220 24TH ST SOUTH

WISCONSIN RAPIDS, WI 54494

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI 54701

MMC - Ladysmith

906 College Ave W

Ladysmith, WI 54848

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Minocqua

9576 Highway 70

MINOCQUA, WI 54548

MMC - Rice Lake

1700 W STOUT ST

RICE LAKE, WI 54868

MMC - River Region at Stevens Point

4100 State Highway 66

Stevens Point, WI 54482

MMC - Weston

3400 Ministry Parkway

WESTON, WI 54476

This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab before and after surgery may work better in treating melanoma.

MC - Chippewa Falls Center

2655 CTY HWY I

CHIPPEWA FALLS, WI 54729

MC - Wausau Center

2727 PLAZA DRIVE

WAUSAU, WI 54401

MC - Wisconsin Rapids Center

220 24TH ST SOUTH

WISCONSIN RAPIDS, WI 54494

MMC - Eau Claire

2310 Craig Rd

Eau Claire, WI 54701

MMC - Ladysmith

906 College Ave W

Ladysmith, WI 54848

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Minocqua

9576 Highway 70

MINOCQUA, WI 54548

MMC - Rice Lake

1700 W STOUT ST

RICE LAKE, WI 54868

MMC - River Region at Stevens Point

4100 State Highway 66

Stevens Point, WI 54482

MMC - Weston

3400 Ministry Parkway

WESTON, WI 54476

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading. standard systemic therapy alone.

MC - Wausau Center

2727 PLAZA DRIVE

WAUSAU, WI 54401

MMC - Eau Claire

2310 Craig Rd

Eau Claire, WI 54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Minocqua

9576 Highway 70

MINOCQUA, WI 54548

MMC - Rice Lake

1700 W STOUT ST

RICE LAKE, WI 54868

MMC - River Region at Stevens Point

4100 State Highway 66

Stevens Point, WI 54482

MMC - Weston

3400 Ministry Parkway

WESTON, WI 54476

zzzDiagnostic & Treatment Center

3401 CRANBERRY BLVD

WESTON, WI 54476

This phase III trial studies how well gemcitabine hydrochloride and cisplatin given with or without nab-paclitaxel work in treating patients with newly diagnosed biliary tract cancers that have spread to other places in the body. Drugs used in chemotherapy, such as gemcitabine hydrochloride, cisplatin, and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not known if giving gemcitabine hydrochloride and cisplatin with or without nab-paclitaxel may work better at treating biliary tract cancers.

MC - Chippewa Falls Center

2655 CTY HWY I

CHIPPEWA FALLS, WI 54729

MC - Wausau Center

2727 PLAZA DRIVE

WAUSAU, WI 54401

MC - Wisconsin Rapids Center

220 24TH ST SOUTH

WISCONSIN RAPIDS, WI 54494

MMC - Eau Claire

2310 Craig Rd

Eau Claire, WI 54701

MMC - Ladysmith

906 College Ave W

Ladysmith, WI 54848

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Minocqua

9576 Highway 70

MINOCQUA, WI 54548

MMC - Rice Lake

1700 W STOUT ST

RICE LAKE, WI 54868

MMC - River Region at Stevens Point

4100 State Highway 66

Stevens Point, WI 54482

MMC - Weston

3400 Ministry Parkway

WESTON, WI 54476

The purpose of the Clinical Registry Investigating Bardet-Biedl Syndrome (CRIBBS) is to establish and perpetuate an international registry enabling subject recruitment for clinical natural history studies, therapeutic trials and collection of biological specimens of blood and saliva specimens of affected individuals and family members with a rare disorder, Bardet-Biedl syndrom (BBS). Biological specimens will be collected for future clinical studies, as well as other studies to examine the relationship between genetic mutations and clinical features. Specimens will be stored in the Core Laboratory.

MC - Chippewa Falls Center

2655 CTY HWY I

CHIPPEWA FALLS, WI 54729

MC - Wausau Center

2727 PLAZA DRIVE

WAUSAU, WI 54401

MC - Wisconsin Rapids Center

220 24TH ST SOUTH

WISCONSIN RAPIDS, WI 54494

MMC - Eau Claire

2310 Craig Rd

Eau Claire, WI 54701

MMC - Ladysmith

906 College Ave W

Ladysmith, WI 54848

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Minocqua

9576 Highway 70

MINOCQUA, WI 54548

MMC - Rice Lake

1700 W STOUT ST

RICE LAKE, WI 54868

MMC - River Region at Stevens Point

4100 State Highway 66

Stevens Point, WI 54482

MMC - Weston

3400 Ministry Parkway

WESTON, WI 54476

This proposal seeks to establish for the first time in Wisconsin a recruitment, data collection and collaborative research site within the CDC¿s multi-site Study to Explore Early Development (SEED) of autism spectrum disorder (ASD). The overall goals of the SEED are to: characterize phenotypic variability and identify relatively homogeneous subgroups of ASD; and investigate risk factors for ASD by comparing the early exposures and development of well-characterized ASD cases and controls selected to represent diverse population subgroups.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

FDA issued a Humanitarian Device Exemption (HDE) approval order for the AMPLATZER PIVSD Occluder (H070005) on January 10, 2017. The conditions of Approval require that SJM conduct a Post approval study to evaluate the safety and probable benefit of the AMPLATZER PIVSD Occluder. In order to evaluate safety and effectiveness of the PIVSD, information will be collected about the procedure in which the device was placed and about how subjects do after the device was placed. This information will be gathered retrospectively, by reviewing medical records for information about the device implant procedure and how the subjects health has been since the device was placed.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

Many patients are treated for advanced cancer without knowledge of underlying molecular features that might indicate FDA approved therapies or potential eligibility for biomarker-selected clinical trials. Strata Oncology is initiating the Strata Trial (STR-001-001) with the primary goal of understanding the proportion of subjects available for clinical trials and approved targeted therapies in advanced cancer while assessing the feasibility of using a large-scale NGS screening program to match subjects for eligibility assessments in clinical trials and/or for approved targeted therapies. The Strata Trial does not require additional procedures but rather uses surplus, or leftover tumor specimens for molecular profiling.

MC - Chippewa Falls Center

2655 CTY HWY I

CHIPPEWA FALLS, WI 54729

MMC - Eau Claire Cancer Center

2200 Craig Road

Eau Claire, WI 54701

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449

MMC - Minocqua

9576 Highway 70

MINOCQUA, WI 54548

MMC - Rice Lake

1700 W STOUT ST

RICE LAKE, WI 54868

MMC - Weston

3400 Ministry Parkway

WESTON, WI 54476

Docosahexaenoic acid (DHA) is a nutrient found in some fish and eggs and its intake in US diets is typically low. Because DHA is important for early brain development, it has recently been added to many prenatal supplements. The usual amount is around 200 mg/day. Participants in this study are guaranteed to receive at least 200 mg/day of DHA. Almost 5 in 100 births in the US occur before 34 weeks of pregnancy. There is no way to predict which births will occur before 34 weeks. In an earlier study conducted at the University of Kansas Medical Center, women who received 600 mg DHA/day compared to no DHA had fewer births before 34 weeks of pregnancy with fewer complications of preterm birth. This study is designed to compare standard care (200 mg/day of DHA) to a higher amount of DHA (1000 mg/day) to determine if the higher amount will reduce early preterm birth (birth before 34 weeks of pregnancy). Individual participation in this study is expected last about 5 months.

MMC - Marshfield

1000 N OAK AVE

MARSHFIELD, WI 54449